Seal Rock Therapeutics, Inc., a US-based clinical stage company, announced on Wednesday that it has signed an out-licensing agreement with GENFIT (Nasdaq:GNFT) (Euronext:GNFT), a France-based biopharmaceutical group, for the development of an injectable formulation of SRT-015 intended for the treatment of acute liver disease, including Acute-on-Chronic Liver Failure (ACLF).
According to the contract, Seal Rock Therapeutics is eligible for payments up to EUR100m including regulatory, clinical, and commercial milestone payments and tiered royalties.
SRT-015 is a highly optimised, second generation, liver-selective inhibitor of Apoptosis Signal-reducing Kinase 1 (ASK1) and is being developed by Seal Rock Therapeutics, in an oral formulation, as a treatment for severe acute alcoholic hepatitis and orphan liver diseases and NASH.
Neil McDonnell, Seal Rock Therapeutics CEO, said, 'We're excited to announce this licensing deal with GENFIT that will accelerate the development of an injectable formulation of our second-generation ASK1 inhibitor SRT-015 for ACLF, a liver disease with high unmet need. At Seal Rock, we remain focused on initiating a Phase 2a trial of oral SRT-015 for severe alcoholic hepatitis. We will also continue development of our first-in-class LRRK2/ASK1 dual kinase inhibitors for Parkinson's Disease and ALS.'
Biotheus expands strategic collaboration with Hansoh Pharmaceutical Group Co
Ionis Pharmaceuticals announces positive results from phase two ION224 study
Prolytix partners with Allumiqs
10x Genomics begins shipping first two products powered by the GEM-X technology architecture
Poseida Therapeutics' P-BCMA-ALLO1 receives US FDA Orphan Drug Designation
AstraZeneca expands rare disease pipeline with Amolyt Pharma acquisition
PureTech's LYT-200 granted FDA orphan drug designation for acute myeloid leukemia treatment
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Sumitomo Pharma Canada announces ORGOVYX (relugolix) prostate cancer drug availability in Canada
Ratio Therapeutics reaches expanded manufacturing agreement with PharmaLogic